在阿尔茨海默氏症和帕金森病中常见的微RNA调节通路
Betina Awuson-David1, Adrian C Williams2, Benjamin Wright2
1School of Biomedical Sciences, Institute of Clinical Sciences, University of Birmingham, Birmingham, United Kingdom.
Frontiers in neuroscience
|September 18, 2023
概括
微RNAs (miRNAs) 与阿尔茨海默氏症和帕金森病有关. 这项研究确定了常见的miRNA通路和潜在的血液生物标志物,如let-7f-5p和miR-29b-3p,用于帕金森病诊断.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 微RNAs (miRNAs) 是基因表达的关键调节者.
- 毫米RNAs的失调越来越多地与神经退行性疾病有关,包括阿尔茨海默病 (AD) 和帕金森病 (PD).
- 目前针对AD和PD的诊断方法往往处于后期阶段,这凸显了早期检测和新的治疗点的必要性.
研究的目的:
- 通过分析miRNA失调来确定阿尔茨海默病和帕金森病之间共同的分子机制和潜在的治疗点.
- 探索基于血液的miRNAs作为神经退行性疾病的生物标志物的实用性.
主要方法:
- 进行了两次独立的系统审查,以对现有的关于AD和PD中miRNA失调的文献进行整理.
- 进行生物信息分析以确定两种疾病之间的共同miRNA和通路 (KEGG).
- 在AD和PD患者的小队列中验证了选择的常见miRNAs的表达.
主要成果:
- 确定了15种常见的miRNA和13种常见的KEGG通路,涉及AD和PD.
- 发现miRNAslet-7f-5p和miR-29b-3p的调节明显失调.
- Let-7f-5p和miR-29b-3p在帕金森病患者的血液中显示出具有预测生物标志物的潜力.
结论:
- 阿尔茨海默病和帕金森病共享共同的基底miRNA介导的生物通路.
- 特定的miRNAs,如let-7f-5p和miR-29b-3p,可以作为帕金森病的宝贵的基于血液的生物标志物.
- 对这些常见途径的进一步研究可能会导致神经退行性疾病的新型共享治疗策略的开发.
更多相关视频
相关概念视频
Parkinson's Disease: Overview
592
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
592
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Parkinson's Disease: Treatment
295
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
295


